RxDoctor Payments Data

Bilal Yousufzai, MD

Ophthalmology · Washington, DCNPI 1023458916

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,290 of the $2,690 with a category attached, or 85.1%. 22 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 25.1% of the total.

$2,690in general payments, 2019–2025

Across 91 payments — averaging $29.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$675
  • Regeneron$400
  • Genentech USA, Inc.$284
  • Astellas Pharma US Inc$220
  • Bausch & Lomb Americas Inc.$202
  • AbbVie$168
  • plus $739 from 16 others

What the payments were for

  • Travel & lodging$40015%
  • Food & beverage$2,29085%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,690 in reported general payments places this provider in the 65th percentile of 74 ophthalmology providers in District of Columbia.

See all ophthalmology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$2,485,557
Medicare patients
847
Services billed
31,333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate111$5,299
Brimonidine Tartrate20$1,542
Ketorolac Tromethamine60$1,211
Difluprednate16$930
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat45$787
Atropine Sulfate15$595
Latanoprost50$465
Ofloxacin33$464
ErythromycinErythromycin Base19$264
Dorzolamide Hcl19$218

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →